DE69535530D1 - Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten - Google Patents
Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile KrankheitenInfo
- Publication number
- DE69535530D1 DE69535530D1 DE69535530T DE69535530T DE69535530D1 DE 69535530 D1 DE69535530 D1 DE 69535530D1 DE 69535530 T DE69535530 T DE 69535530T DE 69535530 T DE69535530 T DE 69535530T DE 69535530 D1 DE69535530 D1 DE 69535530D1
- Authority
- DE
- Germany
- Prior art keywords
- antitoxins
- difficile
- treatment
- humans
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001147 anti-toxic effect Effects 0.000 title abstract 6
- 241000193163 Clostridioides difficile Species 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 108700012359 toxins Proteins 0.000 abstract 3
- 241000271566 Aves Species 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 231100000699 Bacterial toxin Toxicity 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000000688 bacterial toxin Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32915494A | 1994-10-24 | 1994-10-24 | |
US08/405,496 US5919665A (en) | 1989-10-31 | 1995-03-16 | Vaccine for clostridium botulinum neurotoxin |
US42271195A | 1995-04-14 | 1995-04-14 | |
US08/480,604 US5736139A (en) | 1989-10-31 | 1995-06-07 | Treatment of Clostridium difficile induced disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69535530D1 true DE69535530D1 (de) | 2007-08-16 |
Family
ID=27502393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535530T Expired - Lifetime DE69535530D1 (de) | 1994-10-24 | 1995-10-23 | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten |
Country Status (17)
Country | Link |
---|---|
US (1) | US6290960B1 (de) |
EP (2) | EP1041149B8 (de) |
JP (2) | JP2002514886A (de) |
CN (1) | CN1176658A (de) |
AT (1) | ATE366312T1 (de) |
AU (1) | AU709586B2 (de) |
BR (1) | BR9509903A (de) |
CA (1) | CA2203504A1 (de) |
CZ (1) | CZ296806B6 (de) |
DE (1) | DE69535530D1 (de) |
FI (1) | FI971732A (de) |
HU (1) | HUT78048A (de) |
MX (1) | MX9702955A (de) |
NO (1) | NO323305B1 (de) |
NZ (2) | NZ337543A (de) |
PL (1) | PL320214A1 (de) |
WO (1) | WO1996012802A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US8012491B2 (en) | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
WO1998008540A1 (en) * | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
JP2001500730A (ja) * | 1996-09-10 | 2001-01-23 | ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン | ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法 |
WO1998023763A1 (en) * | 1996-11-29 | 1998-06-04 | The General Hospital Corporation | Heterologous antigens in live cell v. cholerae strains |
US7179611B2 (en) * | 1997-02-10 | 2007-02-20 | Bd Lee Laboratories | Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A |
EP1000155A1 (de) * | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogene fragmente des toxins a aus clostridium difficile |
DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
AU754270B2 (en) | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
US6051239A (en) * | 1997-10-20 | 2000-04-18 | Thomas Jefferson University | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US6780617B2 (en) | 2000-12-29 | 2004-08-24 | Chen & Chen, Llc | Sample processing device and method |
EP1097165A4 (de) * | 1998-07-13 | 2001-09-12 | Parkash S Gill | Inhibitoren der angiogenese und des tumorwachstums |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン |
EP1057895A1 (de) * | 1999-06-04 | 2000-12-06 | Lohmann Animal Health GmbH & Co. KG | Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung |
FR2796385A1 (fr) * | 1999-07-16 | 2001-01-19 | Inst Nat Sante Rech Med | Methode de production d'anticorps dans le jaune d'oeuf et utilisation des anticorps ainsi obtenus |
GB9921592D0 (en) | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
UA79735C2 (uk) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
EP1427531B1 (de) | 2001-09-11 | 2016-10-19 | Iquum, Inc. | Probenbehälter |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US7718421B2 (en) | 2003-02-05 | 2010-05-18 | Iquum, Inc. | Sample processing |
US9701737B2 (en) * | 2003-02-19 | 2017-07-11 | Camas, Incorporated | Immunogen adherence and method of making and using same |
EP1766093B1 (de) | 2004-02-06 | 2011-06-15 | University of Massachusetts | Antikörper gegen clostridium difficile-toxine und ihre verwendung |
WO2006017749A2 (en) * | 2004-08-04 | 2006-02-16 | Allergan, Inc. | Optimizing expression of active botulinum toxin type a |
NZ555339A (en) * | 2004-11-24 | 2010-03-26 | Techlab Inc | Device and method for detection of analytes |
GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2007146139A2 (en) * | 2006-06-08 | 2007-12-21 | Cornell Research Foundation, Inc. | Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b |
CN100564527C (zh) * | 2006-10-23 | 2009-12-02 | 中国人民解放军军事医学科学院生物工程研究所 | A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用 |
JP2008169142A (ja) * | 2007-01-11 | 2008-07-24 | Osaka Prefecture Univ | 食中毒菌に対する抗体の産生方法 |
JP5305427B2 (ja) * | 2007-01-11 | 2013-10-02 | 公立大学法人大阪府立大学 | インフルエンザウイルスに対する抗体の産生方法 |
US9802988B2 (en) | 2009-05-20 | 2017-10-31 | University Of Maryland, Baltimore | Engineered type IV pilin of Clostridium difficile |
EP2432500A4 (de) | 2009-05-20 | 2014-03-26 | Univ Maryland | Manipuliertes typ-iv-pilin von clostridium difficile |
EP2519257A4 (de) * | 2009-12-02 | 2014-10-15 | Univ Tufts | Atoxische rekombinante holotoxine aus clostridium difficile als immunogene |
GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
PL2753352T5 (pl) * | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
CN102533867A (zh) * | 2010-12-10 | 2012-07-04 | 西北民族大学 | 一种艰难梭菌a毒素的类毒素的制备方法 |
CN102181457B (zh) * | 2011-03-21 | 2012-07-04 | 王世霞 | 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗 |
BR122019017005B1 (pt) | 2011-04-22 | 2022-03-29 | Wyeth Llc | Composições que se relacionam a uma toxina de clostridium difficile mutante |
PL3138916T3 (pl) * | 2011-05-27 | 2019-11-29 | Glaxosmithkline Biologicals Sa | Kompozycja immunogenna |
US20150071958A1 (en) * | 2011-11-30 | 2015-03-12 | Board Of Trustees Of Michigan State University | Immunological composition for clostridium difficile |
SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
JP6290918B2 (ja) | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
CN103865938B (zh) * | 2012-12-16 | 2016-10-05 | 山东国际生物科技园发展有限公司 | 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用 |
WO2014159510A1 (en) | 2013-03-12 | 2014-10-02 | Yale University | Compositions and methods for identifying secretory antibody-bound microbes |
BE1022949B1 (fr) | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
EP3453396A1 (de) * | 2014-08-28 | 2019-03-13 | Yale University | Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen oder -leiden |
EP3307239B1 (de) | 2015-06-12 | 2020-09-16 | Vaxart, Inc. | Formulierungen zur freisetzung von rsv- und norovirus-antigenen im dünndarm |
JP6855469B2 (ja) * | 2015-10-16 | 2021-04-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 消化器標的療法のための処方物を調製するための工程 |
JP6964623B2 (ja) * | 2017-03-29 | 2021-11-10 | バルネバ オーストリア ジーエムビーエイチ | C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用 |
JP6612807B2 (ja) * | 2017-03-29 | 2019-11-27 | バルネバ オーストリア ジーエムビーエイチ | C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用 |
CN108822211B (zh) * | 2018-06-05 | 2019-12-24 | 中国人民解放军军事科学院军事医学研究院 | 一种制备a、b、e、f型四价肉毒抗毒素的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550019A (en) * | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
ES2052496T3 (es) | 1985-11-25 | 1994-07-16 | Ghen Corp | Sustancia que contiene anticuerpo especifico obtenida de huevos y metodo para su produccion y uso. |
US5831022A (en) * | 1986-02-18 | 1998-11-03 | Hoffmann-La Roche Inc. | Purification of recombinant human IL-1α |
CA1340522C (en) * | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
US5268295A (en) * | 1991-05-31 | 1993-12-07 | W. Alton Jones Cell Science Center, Inc. | Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
JP4102432B2 (ja) * | 1992-09-01 | 2008-06-18 | メルク パテント ゲーエムベーハー | 杉花粉由来のアレルゲン性蛋白質及びペプチド |
JPH06192118A (ja) * | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
JPH06192296A (ja) * | 1992-10-28 | 1994-07-12 | Chiba Pref Gov | 治療用医薬品としての結晶a型ボツリヌス毒素の製造法。 |
US5480972A (en) * | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
-
1995
- 1995-10-23 CN CN95196424A patent/CN1176658A/zh active Pending
- 1995-10-23 PL PL95320214A patent/PL320214A1/xx unknown
- 1995-10-23 WO PCT/US1995/013737 patent/WO1996012802A1/en active IP Right Grant
- 1995-10-23 AT AT00105371T patent/ATE366312T1/de not_active IP Right Cessation
- 1995-10-23 AU AU39683/95A patent/AU709586B2/en not_active Ceased
- 1995-10-23 HU HU9901238A patent/HUT78048A/hu active IP Right Revival
- 1995-10-23 EP EP00105371A patent/EP1041149B8/de not_active Expired - Lifetime
- 1995-10-23 CZ CZ0125097A patent/CZ296806B6/cs not_active IP Right Cessation
- 1995-10-23 NZ NZ337543A patent/NZ337543A/en unknown
- 1995-10-23 NZ NZ295998A patent/NZ295998A/en unknown
- 1995-10-23 DE DE69535530T patent/DE69535530D1/de not_active Expired - Lifetime
- 1995-10-23 CA CA002203504A patent/CA2203504A1/en not_active Abandoned
- 1995-10-23 EP EP95937626A patent/EP0796326A4/de not_active Withdrawn
- 1995-10-23 JP JP51412796A patent/JP2002514886A/ja active Pending
- 1995-10-23 BR BR9509903A patent/BR9509903A/pt not_active Application Discontinuation
-
1997
- 1997-04-23 MX MX9702955A patent/MX9702955A/es unknown
- 1997-04-23 FI FI971732A patent/FI971732A/fi unknown
- 1997-04-23 NO NO19971868A patent/NO323305B1/no unknown
- 1997-08-20 US US08/915,136 patent/US6290960B1/en not_active Expired - Fee Related
-
2002
- 2002-08-20 JP JP2002238940A patent/JP3914484B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0796326A1 (de) | 1997-09-24 |
HUT78048A (hu) | 1999-07-28 |
CZ125097A3 (cs) | 1998-03-18 |
FI971732A (fi) | 1997-06-23 |
CA2203504A1 (en) | 1996-05-02 |
ATE366312T1 (de) | 2007-07-15 |
EP1041149A3 (de) | 2001-05-02 |
EP0796326A4 (de) | 2000-01-19 |
WO1996012802A9 (en) | 1999-09-16 |
EP1041149A2 (de) | 2000-10-04 |
AU709586B2 (en) | 1999-09-02 |
FI971732A0 (fi) | 1997-04-23 |
CZ296806B6 (cs) | 2006-06-14 |
EP1041149B8 (de) | 2007-10-03 |
NO971868L (no) | 1997-06-24 |
JP3914484B2 (ja) | 2007-05-16 |
AU3968395A (en) | 1996-05-15 |
MX9702955A (es) | 1998-07-31 |
EP1041149B1 (de) | 2007-07-04 |
BR9509903A (pt) | 1997-11-25 |
JP2002514886A (ja) | 2002-05-21 |
WO1996012802A1 (en) | 1996-05-02 |
NZ337543A (en) | 2002-06-28 |
PL320214A1 (en) | 1997-09-15 |
CN1176658A (zh) | 1998-03-18 |
NO971868D0 (no) | 1997-04-23 |
US6290960B1 (en) | 2001-09-18 |
NZ295998A (en) | 1999-10-28 |
JP2003137897A (ja) | 2003-05-14 |
NO323305B1 (no) | 2007-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535530D1 (de) | Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten | |
DK534188D0 (da) | Hidtil ukendt vaccine | |
NO20004972L (no) | Derivater av pneumokokkale kolinbindende proteiner for vaksiner | |
DE60032250D1 (de) | Behandlung von Allergien | |
DE3684305D1 (de) | Antivirales immunotherapeutisches mittel und dessen herstellung. | |
AU7814498A (en) | Multivalent (in ovo) avian vaccine | |
CA2022420A1 (en) | Escherichia coli vaccine | |
HUP9801266A2 (hu) | Multimer, rekombináns ureázvakcina | |
PT600396E (pt) | Vacinas contra protozoarios intestinais | |
ATE108335T1 (de) | Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen. | |
HUP9700975A2 (hu) | Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok | |
DE69833568D1 (de) | Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe | |
ATE107661T1 (de) | Hrsv-vakzine. | |
Nguyen et al. | Immunological properties of the chicken egg yolk (IgY) antibodies against Vietnamese cobra Naja Naja venom | |
RU2285539C2 (ru) | Молекулярная бивалентная вакцина для профилактики бруцеллеза и диарей, вызванных энтеропатогенными бактериями | |
ATE196424T1 (de) | Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten | |
EA202100185A3 (ru) | Вакцина и способ повышения иммуногенности и специфической активности средств профилактики инфекций | |
EA200000011A1 (ru) | Средства и способы доставки лекарственных препаратов для терапии вирусных и бактериальных инфекций и синдромов истощения | |
RU96123906A (ru) | Способ и вакцина для профилактики и лечения иммунодефицитов, например рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: ALLERGAN, INC., IRVINE, CALIF., US |
|
8332 | No legal effect for de |